The top 10 drugs losing US exclusivity in 2026

In an era of pharma megablockbusters, industry watchers’ attention naturally drifts toward the biggest drugs in the business. Lately, those ranks have been filled by the ubiquitous diabetes and obesity drugs from Eli Lilly and Novo Nordisk, plus Merck’s cancer superstar Keytruda and other major sales drivers.  | While the industry’s megablockbusters naturally command significant attention, Fierce takes a chance each year to look at older medicines nearing their tumble over the patent cliff.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source